Investor Presentation

77 Investor presentation First six months of 2022 Rare disease sales remains unchanged, driven by commercial execution and key brands EsperoctⓇ and Refixia® DKK billion 20 4% 20 10 NovoSevenⓇ and NorditropinⓇ account for ~75% of Rare disease sales 1% 4% Rare disease franchise is back to growth DKK billion 0% 4% 1% 20 10 4% 8 7 7 0% 4 11 12 12 6 0 0 2019 2020 2021 H1 2022 2019 NovoSevenⓇ NorditropinⓇ Other haemophilia products¹ Other Rare disease Growth at CER Source: Quarterly company announcement Note: Company reported sales; CER: Constant exchange rates; 1Other haemophilia products primarily consists of Vagifem® and ActivelleⓇ 2020 2021 H1 2022 IO NAO Growth at CER Novo NordiskⓇ

View entire presentation